For Roche Holding AG, collaborating with technology start-ups is no longer enough. Now it wants to own them.
The Swiss oncology giant bought three tech companies and joined forces with another in the past eight months as it seeks to take advantage of a flood of data from patients and clinical studies. The most recent deal, a US$1.9 billion takeover of Flatiron Health Inc, gives it a platform to comb through medical records, gene sequences and insurance claims to find out what cancer therapies work.
“Real-world data — and all the associated analytical tools, like machine learning — this is a field which will get very important for research and development” and eventually for reimbursement, Roche chief executive officer Severin Schwan said in an interview late last year. “We have made very conscious decisions to explore into this direction in a more strategic way, not just to stumble into it.”
Drugmakers and the insurers that decide whether therapies will be reimbursed are looking for evidence to guide both the development of new products and the use of treatments after they are approved. Roche’s Flatiron deal is a harbinger of more deals to come, especially in the demanding field of oncology, said Pierre Corby, a Paris-based analyst for Oddo & Cie.
“It’s more and more complicated in the space of oncology to find the right treatment for the right person,” Corby said by telephone. “Even very smart oncologists have difficulties right now finding the right treatments and the right doses.”
The Flatiron deal is expected to close in the first half of this year.
The New York-based health-data start-up was founded by Nat Turner and Zach Weinberg. Roche already owns almost 13 percent of Flatiron after leading a US$175 million funding round in 2016. The company has raised more than US$300 million from investors such as Google parent Alphabet Inc and First Round Capital.
Flatiron’s technology is also aimed at enabling doctors to look at how other patients fare with various therapies and use those results to customize treatment for patients with similar illnesses. These personalized approaches have become an important part of treating cancer, where therapies often have very different results in patients whose disease appears similar.
The pharma industry is increasingly turning to huge databases to gain understanding of complex interactions between drugs and organisms, and the overall impact that treatments have on the outcomes of health problems.
AstraZeneca PLC is ramping up its use of such real-world patient information to better understand the diseases it is aiming at, as well as study drugs in development, according to Ludovic Helfgott, the vice president of the drugmaker’s cardiovascular, metabolism and renal unit.
Analyzing data aggregated from patients’ medical records can help confirm or question observations from more rigorous randomized controlled trials, he said.
“You can have very quickly a massive amount of information that’s clinically relevant,” Helfgott said in an interview last month.
Meanwhile, Roche and General Electric Co’s health division made a deal last month to develop software to help oncologists make care decisions more quickly. In November last year, Roche bought Viewics Inc, an analytics company that helps laboratories parse data to make business strategy decisions. And in June, Roche acquired mySugr, an app that helps people with diabetes track their blood glucose levels.
The Swiss company also holds more than half of the shares of Foundation Medicine Inc, which helps doctors and patients choose treatments based on the tumors’ genetic profiles.
Stephen Garrett, a 27-year-old graduate student, always thought he would study in China, but first the country’s restrictive COVID-19 policies made it nearly impossible and now he has other concerns. The cost is one deterrent, but Garrett is more worried about restrictions on academic freedom and the personal risk of being stranded in China. He is not alone. Only about 700 American students are studying at Chinese universities, down from a peak of nearly 25,000 a decade ago, while there are nearly 300,000 Chinese students at US schools. Some young Americans are discouraged from investing their time in China by what they see
MAJOR DROP: CEO Tim Cook, who is visiting Hanoi, pledged the firm was committed to Vietnam after its smartphone shipments declined 9.6% annually in the first quarter Apple Inc yesterday said it would increase spending on suppliers in Vietnam, a key production hub, as CEO Tim Cook arrived in the country for a two-day visit. The iPhone maker announced the news in a statement on its Web site, but gave no details of how much it would spend or where the money would go. Cook is expected to meet programmers, content creators and students during his visit, online newspaper VnExpress reported. The visit comes as US President Joe Biden’s administration seeks to ramp up Vietnam’s role in the global tech supply chain to reduce the US’ dependence on China. Images on
New apartments in Taiwan’s major cities are getting smaller, while old apartments are increasingly occupied by older people, many of whom live alone, government data showed. The phenomenon has to do with sharpening unaffordable property prices and an aging population, property brokers said. Apartments with one bedroom that are two years old or older have gained a noticeable presence in the nation’s six special municipalities as well as Hsinchu county and city in the past five years, Evertrust Rehouse Co (永慶房產集團) found, citing data from the government’s real-price transaction platform. In Taipei, apartments with one bedroom accounted for 19 percent of deals last
US CONSCULTANT: The US Department of Commerce’s Ursula Burns is a rarely seen US government consultant to be put forward to sit on the board, nominated as an independent director Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, yesterday nominated 10 candidates for its new board of directors, including Ursula Burns from the US Department of Commerce. It is rare that TSMC has nominated a US government consultant to sit on its board. Burns was nominated as one of seven independent directors. She is vice chair of the department’s Advisory Council on Supply Chain Competitiveness. Burns is to stand for election at TSMC’s annual shareholders’ meeting on June 4 along with the rest of the candidates. TSMC chairman Mark Liu (劉德音) was not on the list after in December last